A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Sulzmaier, 2014, FAK in cancer: mechanistic findings and clinical applications, Nature Rev Cancer, 14, 598, 10.1038/nrc3792 Thapa, 2014, Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr925, Biochem Biophys Res Comm, 1696, 1701 Zhao, 2009, Signal transduction by focal adhesion kinase in cancer, Cancer Metastasis Rev, 28, 35, 10.1007/s10555-008-9165-4 McLean, 2005, The role of focal adhesion kinase in cancer: a new therapeutic opportunity, Nat Rev Cancer, 5, 505, 10.1038/nrc1647 Ozkal, 2009, Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues, Path Res Prac, 205, 781, 10.1016/j.prp.2009.07.002 Recher, 2004, Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis, Cancer Res, 64, 3191, 10.1158/0008-5472.CAN-03-3005 Ding, 2010, Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival, Trans Res, 156, 45, 10.1016/j.trsl.2010.05.001 Sood, 2004, Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion, Am J Path, 165, 1087, 10.1016/S0002-9440(10)63370-6 Auger, 2012, The focal adhesion kinase inhibitor GSK2256098: a potent and selective inhibitor for the treatment of cancer, Eur J Cancer, 48, 118, 10.1016/S0959-8049(12)72185-8 Chen, 2012, Pharmacological inhibition of focal adhesion kinase (FAK) in glioblastoma cell lines: implications for rational drug combination strategies, Cancer Res, 72 Bottsford-Miller, 2011, Enhancing anti-angiogenic therapy by blocking focal adhesion kinase, Cancer Res, 71 Doughty, 2012, Anti-tumour activity of the focal adhesion kinase inhibitor GSK2256098C in ovarian cancer, Eur J Cancer, 48, 173 Simon, 1997, Accelerated titration designs for phase I clinical trials in oncology, J Natl Cancer Inst, 89, 1138, 10.1093/jnci/89.15.1138 Eisenhauer, 2009, New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1), Eur J Cancer., 45, 228, 10.1016/j.ejca.2008.10.026 Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059 Fizazi, 2007, High detection rate of circulating tumor cells in blood of subjects with prostate cancer using telomerase activity, Ann Oncol., 18, 518, 10.1093/annonc/mdl419 Taylor, 2009, High levels of circulating VEGFR2+ bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies, Clin Cancer Res, 15, 4561, 10.1158/1078-0432.CCR-08-2363 Jacques, 2008, Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay, J Immunol Method, 337, 132, 10.1016/j.jim.2008.07.006 Arkenau, 2015, A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.2593 Sekido, 2013, Molecular pathogenesis of malignant mesothelioma, Carcinogenesis, 34, 1413, 10.1093/carcin/bgt166 Poulikakos, 2006, Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK, Oncogene, 25, 5960, 10.1038/sj.onc.1209587 Shapiro, 2014, Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship, Science Trans Med, 6, 237, 10.1126/scitranslmed.3008639 Krug, 2015, Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial, Lancet Oncol, 16, 447, 10.1016/S1470-2045(15)70056-2 Brastianos, 2013, Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations, Nat Genet, 45, 285, 10.1038/ng.2526 Jones, 2015, A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors, Invest New Drugs, 33, 1100, 10.1007/s10637-015-0282-y Zalcman, 2015, Bevacizumab 15 mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in malignant pleural mesothelioma (MPM): results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.7500